08/20/2026
Researchers at Tel Aviv University have presented new findings indicating that the experimental drug Davunetide may significantly slow the progression of progressive supranuclear palsy (PSP) in women, who exhibited a markedly different response to treatment than men. These results reinforce the need for sex-specific medicine in neurodegenerative diseases.
The new publication, led by Prof. Illana Gozes of the Sagol School of Neuroscience and the Gray Faculty of Medical and Health Sciences at TAU, used updated FDA-recommended outcome measures to reanalyze data from a 52-week international clinical trial involving more than 300 patients with PSP, a rare and fatal neurodegenerative disease caused by the abnormal accumulation of tau protein in the brain. There is currently no effective drug treatment for the disease.
Read more: https://cftau.ca/experimental-treatment-slows-fatal-brain-disease-in-women/
Tel Aviv University | אוניברסיטת תל-אביב
Sagol School of Neuroscience TAU ביה"ס סגול למדעי המוח אונ’ ת"א